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Glucocorticoid hormones (GCs) are critical for survival since they ensure the energy 
supply necessary to the body in an ever challenging environment. GCs are known to 
act on appetite, glucose metabolism, fatty acid metabolism, and storage. However, 
to be beneficial to the body, GC levels should be maintained in an optimal window of 
concentrations. Not surprisingly, conditions of GC excess or deficiency, e.g., Cushing’s 
syndrome or Addison’s disease, are associated with severe alterations of energy metab-
olism. Corticosteroid-binding globulin (CBG), through its high specific affinity for GCs, 
plays a critical role in regulating plasma GC levels and their access to target cells. Genetic 
studies in various species including humans have revealed that CBG is the major factor 
influencing interindividual genetic variability of plasma GC levels, both in basal and stress 
conditions. Some, but not all, of these genetic studies have also provided data linking 
CBG levels to body composition and insulin levels. The examination of CBG-deficient 
mice submitted to hyperlipidic diets unveiled specific roles for CBG in lipid storage and 
metabolism. An influence of CBG on appetite has not been reported but remains to be 
more finely analyzed. Finally, only male mice have been examined under high-fat diet, 
while obesity is affecting women even more than men. Overall, a role of CBG in GC-driven 
metabolic disorders is emerging in recent studies. Although subtle, the influence of CBG 
in these diseases could open the way to new therapeutic interventions since CBG is 
easily accessible in the blood.
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inTRODUCTiOn
Glucocorticoid hormones (GCs) are adrenal cortex steroids that were named from their role in the 
regulation of glucose metabolism, mostly through maintaining the reserves of glycogen in the liver. 
They also play an intricate role in fatty acid metabolism and storage. Finally, they are also important 
regulators of appetite through complex interactions with orexigenic and anorexigenic neuropeptides 
and hormones. Excess GC levels, encountered in Cushing’s syndrome or GC therapy, lead to central 
obesity associated with hyperphagia, insulin resistance, and fatty liver development (1).
Under normal physiological conditions, GC secretion (cortisol or corticosterone depending 
on species) follows a circadian rhythm entrained by light and food intake. These environmental 
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stimuli trigger the secretion of the hypothalamic peptide corti-
cotrophin-releasing hormone (CRH), which, in turn, stimulates 
pituitary secretion of adrenocorticotrophic hormone (ACTH) 
that acts on adrenal glands to induce GC synthesis and release 
in the blood (2). In plasma, GCs bind with a high affinity but 
low capacity to transcortin, also called corticosteroid-binding 
globulin (CBG), and to albumin with a high capacity but low 
affinity (3, 4). The free fraction of circulating GCs thus con-
stitutes around 3–5% of the total GC pool. Free GCs regulate 
negatively their own secretion by inhibiting CRH and ACTH 
release and act on target tissues by binding to specific receptors, 
the mineralocorticoid and the GC receptors (5). Under stressful 
conditions, the increase in CRH levels results in increased GC 
secretion that must be transient to be protective to the body. 
GCs are essential for survival but not enough or too much GC 
signaling is deleterious for health (6).
Corticosteroid-binding globulin has been known since 1956 
as a plasma protein capable of high-affinity interaction with 
cortisol (4). It was purified in the early 60s and cloned and 
characterized since the 90s in many species (7). Recently, CBG 
has been identified as a major component of GC genetic vari-
ability in animals and humans. Consequently, the role of CBG in 
GC-driven metabolic disorders and obesity gained interest. This 
mini-review summarizes the recent studies related to the role of 
CBG in GC-driven metabolic alterations and obesity.
GeneTiC STUDieS HiGHLiGHTinG  
THe CenTRAL ROLe OF CBG in GC 
vARiABiLiTY
Large individual differences exist in both basal and stress-
induced GC levels. Because this variability is in part of genetic 
origin, several research groups have used genetic mapping on 
experimental crosses, i.e., a non-hypothesis-driven approaches, 
to identify genetic factors contributing to this variability of GC 
levels (8, 9). The first study to demonstrate the importance of 
CBG used contrasted pig breeds, the Chinese Meishan vs. the 
European Large White breed (10). The former shows plasma 
cortisol concentrations higher than most European pig breeds, 
as well as a reduced growth rate, low muscle content, and high-
fat deposits, all features that may be consequences of their high 
cortisol levels (11). This genetic mapping study resulted in the 
detection of a locus containing the gene encoding CBG (called 
SerpinA6), strongly associated with cortisol levels, in particular 
stress levels, and explaining 20% of the variance in the F2 popula-
tion (12). Because CBG was posited as a serious candidate gene of 
cortisol variability, it was thus investigated further in a follow-up 
study. New arguments in favor of its involvement were provided 
by a genetic mapping analysis on the same F2 pig intercross using 
CBG levels as a trait instead of cortisol. This genetic mapping 
detected exactly the same genomic locus than when using cortisol 
levels with higher statistical strength. In addition, CBG mRNA 
and binding capacity were found different between the parental 
pig breeds, i.e., higher levels in the Meishan breed (13).
Few years later, a similar genetic mapping approach was used 
in rodent models. The genome scan detected a highly significant 
quantitative trait locus associated with poststress corticosterone at 
the SerpinA6/CBG locus. The cDNA sequence analysis of paren-
tal strains revealed a Met276Ile mutation in WKY rat identical to 
that found in the Biobreeding rat strain that exhibits decreased 
CBG binding affinity for corticosterone (14). More recently, a 
series of studies conducted in different pig lines confirmed the 
genetic linkage or genetic association between SerpinA6/CBG 
locus and basal cortisol levels in pig (15–18). Finally, in humans, 
a very significant association between the SERPINA6/SERPINA1 
locus and morning plasma cortisol concentrations was reported 
in a genome-wide association meta-analysis using ~2.5 M SNPs 
in 12,597 Caucasian subjects, replicated in 2,795 participants 
(19). Further investigation using part of the cohort showed 
that common SNPs in this locus were associated with variation 
in plasma CBG concentrations. These data were replicated in a 
recent candidate gene study, where SNPs within the SERPINA6 
gene were also found associated with morning cortisol and CBG 
concentrations in a cohort of 1,077 adolescents (20).
In conclusion, CBG appears to be a major component of 
GC genetic variability in various mammalian species including 
humans. Given the role of GC in energy metabolism, the asso-
ciation of the locus CBG with body composition and metabolic 
parameters has also been investigated.
GeneTiC STUDieS ReLATinG CBG  
AnD BODY COMPOSiTiOn
In the first pig study, genetic linkage between the CBG locus 
and several parameters of body composition was found, namely, 
backfat weight and thickness, as well as muscle content (13). 
Interestingly, in this study, plasma CBG levels appeared to be a 
better predictor of body composition than cortisol levels, as CBG 
binding capacity showed negative correlation to muscle and 
positive ones to fat deposits, whereas no significant correlation 
was found between the same traits and cortisol concentrations. 
Later, a correlation between the percentage of fat and CBG 
binding capacity was replicated in a Meishan × Large White F10 
intercross (21). However, no genetic linkage to body composition 
traits was detected in another pig study involving a different breed 
(Duroc instead of Meishan) (15).
In rodents, many genetic studies have detected adiposity, body 
weight, insulin levels, or diabetes susceptibility to the locus con-
taining CBG without necessarily testing or even invoking CBG 
as the causal gene (7).
In humans, a genetic analysis was conducted in a cohort of 
44 obese premenopausal women using a genetic marker within 
the CBG gene (22). No association was found with metabolic or 
obesity parameters and the CBG genetic marker. However, in 
patients holding a specific allele of the CBG marker (allele 90), a 
strong correlation was found between salivary cortisol after dexa-
methasone suppression test and waist-to-hip ratio, whereas this 
correlation was not significant for the other patients of the cohort. 
These results suggest that CBG gene polymorphisms may modu-
late the influence of the HPA axis on the fat mass distribution in 
this sample of obese women. In a second study, the same genetic 
marker in CBG gene was used to genotype a population of 295 
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men with body mass index (BMI) ranging from 19 to 55 kg/m2 
(23). The frequency of the allele 90 was found markedly increased 
among men with morbid obesity (BMI > 40) compared to the 
rest of the population. Furthermore, the CBG polymorphism was 
found correlated with BMI and waist circumference in the total 
population. Finally, this CBG gene polymorphism was also used 
in a cohort of 45 prepubertal obese children. No differences were 
found for obesity or metabolic parameters between genotypes at 
the CBG locus, although allele 90 carriers presented increased 
24-h free urinary cortisol (24).
Overall, the genetic studies revealed a modest influence of 
CBG on body composition and obesity. This modest influence 
of CBG may be explained by the complexity of the regulation of 
these traits as well as the small size of the populations studied.
DiSSeCTinG MeTABOLiC ALTeRATiOnS 
in CBG-DeFiCienT MOUSe MODeLS
Older studies have reported altered levels of CBG in animal 
models of obesity. For example, the obese Zucker rat presents 
plasma and adipose tissue CBG levels twice lower than its lean 
control. Furthermore, in the obese Zucker rat, the regulation of 
CBG by GCs is lost (25, 26). However, in the Obese strain chicken 
model, contrary to the obese Zucher rat, CBG is found twice as 
high as compared with its healthy control (27). The availability 
of CBG-deficient mice produced by specific knockout of the 
SerpinA6 gene provided the opportunity to clarify the specific 
role of CBG in obesity.
A mouse model of CBG deficiency has been first reported in 
Petersen et al. (28). When submitted to a 6-week-long high-fat 
diet (HFD: 26 vs. 4% kcal fat for control diet), Cbg KO showed 
a tendency (p  =  0.08) for increased body weight compared 
to WT. However, the weight loss, as well as liver gene expres-
sion estimated by gene arrays, was found equivalent between 
genotypes after 36 h of food deprivation. Using the same mouse 
model, a recent study examined the metabolic consequences of 
a 12-week-long very HFD (60 vs. 18% kcal fat for control diet) 
on body weight, white adipose tissue, and liver (29). Under the 
very HFD, total body weight gain and food intake were similar 
in both Cbg KO and WT groups. Interestingly, Cbg KO mice 
presented a significantly lower subcutaneous white adipose tis-
sue accumulation than WT mice, associated with a slight higher 
increase in retroperitoneal and epididymal fat, but no differences 
in mesenteric fat depots. Adipocytes size increased with HFD in 
both WT and Cbg KO. However, in agreement with the depot-
specific fat weights, the increase in adipocytes’ size was smaller 
in the subcutaneous fat from Cbg KO than WT, but bigger in the 
epididymal fat. Total lipid content in liver of animals under HFD 
was equivalent between genotypes, but the accumulation of lipids 
in liver under HFD compared to control diet was found higher 
in Cbg KO compared to WT. HFD similarly increased serum 
glucose, insulin, leptin, and cholesterol in both genotypes. Non-
esterified fatty acids, triacylglycerols, and urea differed neither 
between diets nor between genotypes.
In both studies, total corticosterone levels were much lower, 
whereas free corticosterone levels were higher in Cbg KO 
compared to WT under both control and HFD in blood sampled 
in the morning, i.e., at the nadir of secretion in mice. CBG and 
total corticosterone levels were increased by the 60% HFD in 
WT, but free corticosterone was not changed as CBG was also 
increased. Cbg KO displayed a modest increase in total and free 
corticosterone under HFD. In both studies, overall no differences 
in liver mRNA expression were detected between genotypes 
under any of the diets, even for GC target genes, such as phospho-
enolpyruvate carboxykinase (PEPCK), tyrosine aminotransferase 
(TAT), or glucose 6-phosphatase (G6PT), in contradiction with 
the finding of increased free corticosterone in Cbg KO. In the 
study by Gulfo et al., a global genotype effect was found for liver 
11-beta hydroxysteroid dehydrogenase type 2 (11HSD2), which 
showed reduced expression in Cbg KO mice and a genotype by 
diet interaction detected for hexose-6-phosphate dehydrogenase 
(H6PDH) which expression increased under HFD in Cbg KO 
contrary to WT. Within fat depots, an opposite pattern of expres-
sion was found in epididymal fat, i.e., 11HSD2 was increased 
in Cbg KO as compared to WT, both under control diet and 
HFD, while 11HSD2 mRNA was very low in subcutaneous fat 
in both genotypes regardless of the diet. The authors discuss 
these results as a within-tissue mechanism to regulate GC excess, 
based on the finding that 11HSD1 and 11HSD2 strongly regulate 
local availability of GC. In liver, low 11HSD2 expression would 
normalize GC signaling by reducing the availability of 11-dehy-
drocorticosterone that is a substrate of 11HSD1 for regeneration 
of corticosterone. In epididymal fat, increased 11HSD2 mRNA 
would inactivate GC, by metabolizing corticosterone in 11-dehy-
drocorticosterone, as a way to counteract the enlargement of 
adipocyte area. These interpretations may explain the lack of vari-
ation between genotypes in mRNA expression of GC target genes 
in some tissue, despite higher free GC levels in Cbg KO. However, 
data collected by our group in Bordeaux provide another line of 
discussion on these data.
We have also generated a Cbg KO mouse model (30) by first 
constructing a mouse line floxed for the gene Cbg and then 
crossing these mice with CMV-Cre mice. In our studies, total 
and free corticosterone levels were measured not only in the 
morning (9:00 a.m.) but also in the evening (9:00 p.m.) when 
the secretion of GC is at its peak (mice are nocturnal animals). 
In the morning, we found increased free GC levels in Cbg KO as 
in the study by Gulfo et al. (29) or Petersen et al. (28), but in the 
evening, this genotype difference was no longer present because 
the higher total GC levels in WT compensated the increased free 
GC percentage in Cbg KO. Thus, the lack of genotype effect on 
mRNA expression in basal conditions is expected since when free 
GC are high (at night), there are no genotype differences in their 
levels.
There is a discrepancy between our reports and those of 
Petersen et al. (28) and Gulfo et al. (29), on the levels of free GC 
measured after stress, when the rise in GC is important. The lat-
ter found either no significant differences in free GCs after stress 
between WT and Cbg KO or increased levels for Cbg KO, whereas 
we have shown that Cbg KO show a hypoglucocorticoid response 
to stress compared to WT (31, 32), including after chronic stress 
(33). Furthermore, Petersen et  al. (28) found a phenotype of 
hyporesponsiveness to GC after septic shock in the Cbg KO mice. 
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To explain this paradox, they hypothesized that Cbg KO mice 
have become insensitive to high levels of free GC, but they did 
not provide data on the mechanism involved. On their side, Gulfo 
et al. (29) found higher free GC levels in Cbg KO mice, both under 
normal and very HFD, associated with lower thymus and higher 
adrenals weight, thereby pleading in favor of chronically elevated 
free GC levels. Taken together, the data from the different groups 
are confusing regarding whether Cbg KO mice are a model of 
hyper- or hypocorticosteronism. We believe that methodological 
differences are another point to take in account. We have used 
isotopic dilution to precisely evaluate free GC, while the other 
groups have measured free GC directly in the serum samples for 
levels that are at the limit of ELISA detection. In their studies, free 
GC levels are lower than expected in WT mice (0.7 and 1% of the 
total corticosterone, respectively, instead of 7–10% in our stud-
ies). This conflicting data will be important to clarify to interpret 
the data obtained on metabolic alteration in Cbg KO mice.
UnRAveLinG THe ROLe OF CBG in 
HUMAn MeTABOLiC DiSORDeRS AnD 
OBeSiTY
In humans, plasma CBG was found to be a marker of insulin 
secretion, being negatively or positively correlated with various 
markers of obesity (BMI and waist-to-hip ratio) depending on the 
degree of insulin resistance (34, 35). Indeed, insulin was shown 
to downregulate CBG levels in vitro (36), thereby providing an 
explanation of low CBG levels in obese hyperinsulinemic subjects 
and high levels of CBG in diabetic insulin-resistant patients. 
Plasma levels of CBG were also found to correlate with some 
markers of the metabolic syndrome (fasting glucose, insulin 
resistance, and adiponectin) and inflammation (interleukin-6 
and C reactive protein) (37–39).
By virtue of its SERPIN structure, CBG is cleaved by the 
serine protease neutrophil elastase, thereby reducing markedly 
GC binding and enabling massive local delivery of GCs at the 
site of inflammation (40). Because elevated levels of elastase have 
been associated with obesity and insulin resistance (41), a recent 
study examined the respective levels of high- and low-affinity 
CBG forms, in a cohort of 100 volunteers. Surprisingly, CBG 
cleavage was found to be reduced in subjects with central obesity 
and metabolic syndrome, which was interpreted as the sign of 
altered CBG protein in obesity that would no longer be sensitive 
to elastase cleavage. The mechanism of reduced CBG cleavage in 
obese patients remains to be described (42).
COnCLUSiOn
From the literature, it is now well established that CBG is a major 
factor influencing GCs levels and thus GCs action in tissues. The 
genetic studies provided hints that CBG was associated with 
increased fat deposits. Few studies have investigated the direct 
effects of CBG on energy metabolism and obesity. In a model 
of CBG deficiency in male mice, CBG seems to play a role in 
lipid metabolism and storage associated with changes in enzymes 
controlling local GC availability when animals are submitted to a 
60% HFD. A potential effect on appetite is not reported, but this 
function has been studied only grossly. For example, examination 
of the pattern of eating through the day and the night or nutrient 
preferences may reveal a role for CBG. In addition, the status of 
GC activity in Cbg KO mice is contradictory in the literature, 
precluding clear-cut interpretation of the effect of CBG deficiency 
on GC-driven metabolism.
Overall, a role of CBG in GC-driven metabolic disorders is 
emerging but in extreme conditions of very hyperlipidic diets. 
The role of elastase in obesity and its regulation of CBG binding 
affinity have opened new avenues of research. Another area not 
explored yet is the influence of changes in temperature on CBG 
binding in the context of obesity. The liver being a very metabolic 
organ with a higher temperature than surrounding tissues, CBG 
affinity for GCs is probably diminished there. The influence of 
CBG in metabolic diseases is probably subtle but could be prom-
ising as a therapeutic target, given that CBG is easily accessible 
in the blood.
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